Novo Nordisk (NOVOB DC) announced new multi-month subscription program for Wegovy for eligible self-pay patients; subscription program to be available from March 31st through Ro, Weightwatchers, LifeMD ; Hims & Hers (HIMS), Sesame & others to follow soon

Novo Nordisk's introduction of a subscription program for Wegovy reflects a strategic move to enhance accessibility for self-pay patients, which may boost sales and deepen market penetration in the obesity management space.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

ECB's Radev says past inflation shocks have left a “durable imprint" and external shocks feeding into price expectations

EU's Costa urged Iran to engage with UN over ensuring freedom of navigation in Strait of Hormuz

Novo Nordisk (NOVOB DC) announced new multi-month subscription program for Wegovy for eligible self-pay patients; subscription program to be available from March 31st through Ro, Weightwatchers, LifeMD ; Hims & Hers (HIMS), Sesame & others to follow soon

Russia's Sibir says equipment malfunction is behind the earlier incident at the plant, according to a prelim assessment

Hershey (HSY) reaffirms net sales and EPS guidance for FY26; unveiled strategy to lead next generation snacking at 2026 investor day

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Wegovy pen all doses subscription plans for 3-months at USD 329/month, 6-months at USD 299/month, 12-months at USD 249/month.
  • Wegovy pill 9 mg, 25 mg doses subscription plans for 3-months at USD 289/month, 6-months at USD 269/month, 12-months at USD 249/month.
Context

The tiered pricing structure over multiple months suggests they are positioning Wegovy as an attractive long-term solution, potentially leading to increased customer retention and revenue stability. This initiative could be seen positively by investors, indicating the company’s commitment to expanding its patient base and revenue streams.

Related headlines

The whole workspace, free to try.

Try it free